1. Home
  2. ENOV vs ARQT Comparison

ENOV vs ARQT Comparison

Compare ENOV & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENOV
  • ARQT
  • Stock Information
  • Founded
  • ENOV 1995
  • ARQT 2016
  • Country
  • ENOV United States
  • ARQT United States
  • Employees
  • ENOV N/A
  • ARQT 342
  • Industry
  • ENOV Fluid Controls
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENOV Industrials
  • ARQT Health Care
  • Exchange
  • ENOV Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • ENOV 2.1B
  • ARQT 1.7B
  • IPO Year
  • ENOV 2008
  • ARQT 2020
  • Fundamental
  • Price
  • ENOV $33.10
  • ARQT $13.52
  • Analyst Decision
  • ENOV Buy
  • ARQT Strong Buy
  • Analyst Count
  • ENOV 4
  • ARQT 6
  • Target Price
  • ENOV $58.50
  • ARQT $18.80
  • AVG Volume (30 Days)
  • ENOV 986.0K
  • ARQT 2.1M
  • Earning Date
  • ENOV 05-08-2025
  • ARQT 05-06-2025
  • Dividend Yield
  • ENOV N/A
  • ARQT N/A
  • EPS Growth
  • ENOV N/A
  • ARQT N/A
  • EPS
  • ENOV N/A
  • ARQT N/A
  • Revenue
  • ENOV $2,150,191,000.00
  • ARQT $212,819,000.00
  • Revenue This Year
  • ENOV $7.13
  • ARQT $57.99
  • Revenue Next Year
  • ENOV $6.33
  • ARQT $41.24
  • P/E Ratio
  • ENOV N/A
  • ARQT N/A
  • Revenue Growth
  • ENOV 18.32
  • ARQT 100.03
  • 52 Week Low
  • ENOV $29.32
  • ARQT $6.99
  • 52 Week High
  • ENOV $53.84
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • ENOV 41.77
  • ARQT 42.59
  • Support Level
  • ENOV $33.48
  • ARQT $12.42
  • Resistance Level
  • ENOV $35.62
  • ARQT $15.67
  • Average True Range (ATR)
  • ENOV 1.32
  • ARQT 0.87
  • MACD
  • ENOV 0.20
  • ARQT -0.03
  • Stochastic Oscillator
  • ENOV 49.20
  • ARQT 33.69

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: